Consequently, it becomes imperative to ascertain whether plasma biomarkers can serve not only in selecting patients with high Aβ for therapy but also in distinguishing different AD biological PET stages (i.e., different levels of tau burden). Here, MAPT is linked to Alzheimer disease.